BridgeBio Oncology Therapeutics’s (BBOT) Moving Averages Convergence Divergence (MACD) indicator is -0.42, suggesting BridgeBio Oncology Therapeutics is a Sell.
BridgeBio Oncology Therapeutics’s (BBOT) 20-Day exponential moving average is 2.30, while BridgeBio Oncology Therapeutics’s (BBOT) share price is $1.81, making it a Sell.
BridgeBio Oncology Therapeutics’s (BBOT) 50-Day exponential moving average is 3.45, while BridgeBio Oncology Therapeutics’s (BBOT) share price is $1.81, making it a Sell.
BridgeBio Oncology Therapeutics’s (BBOT) 10-Day exponential moving average is 2.04, while BridgeBio Oncology Therapeutics’s (BBOT) share price is $1.81, making it a Sell.
BridgeBio Oncology Therapeutics’s (BBOT) 100-Day exponential moving average is 5.05, while BridgeBio Oncology Therapeutics’s (BBOT) share price is $1.81, making it a Sell.
BridgeBio Oncology Therapeutics’s (BBOT) stock price is $1.81 and BridgeBio Oncology Therapeutics’s (BBOT) 50-day simple moving average is 3.14, creating a Sell signal.
BridgeBio Oncology Therapeutics’s (BBOT) stock price is $1.81 and BridgeBio Oncology Therapeutics’s (BBOT) 100-day simple moving average is 5.89, creating a Sell signal.
BridgeBio Oncology Therapeutics’s (BBOT) stock price is $1.81 and BridgeBio Oncology Therapeutics’s (BBOT) 200-day simple moving average is 7.40, creating a Sell signal.